Luyan Pharma Stock Forum

Investors expect Luyan Pharma Co.,Ltd.'s limited growth rates to continue, contributing to its low P/E ratio. The recent medium-term earnings trends, worse than market expectations, also play a part. Investors believe the potential for earnings improvement doesn't justify a higher P/E ratio.

Even though EPS growth at Luyan Pharma outstripped its share price rise, the market is skeptical due to the stock's low P/E ratio. Moreover, the significant part dividends play in total shareholder return points towards an appreciated dividend policy.